Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:12:34.382Z.
Calculation as of: 2026-10-06T19:12:34.382Z.
Quote observation: 2026-10-06T19:10:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d2baa5019f568993ecceb1943c30cf17443c8d153a00c2cc4d930c3e59df60e4
PE RATIO
N/A
Liminatus Pharma, Inc. Class A Common Stock
Market Cap
$5.12M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.06M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $5.12M | N/A | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $5.06M | N/A | 1.64 | 1.64 | 1.64 |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.06M | N/A | N/A | N/A | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.03M | N/A | N/A | N/A | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | N/A | N/A | N/A | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.23M | N/A | N/A | N/A | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.23M | N/A | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | N/A | N/A | N/A | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.28M | N/A | N/A | N/A | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.31M | N/A | 56.51 | 56.51 | 56.51 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
